<noscript id="w5p92"><object id="w5p92"></object></noscript>

    1. <nav id="w5p92"><code id="w5p92"></code></nav>

      <nav id="w5p92"></nav>
    2. <dd id="w5p92"></dd>
    3. <nav id="w5p92"><optgroup id="w5p92"></optgroup></nav>

        For the latest updates on our ongoing response to COVID-19, please click here.

        Company Statements

        04/10/2020

        Gilead Sciences Response to Médecins Sans Frontières

        03/25/2020

        Gilead Sciences Statement on Request to Rescind Remdesivir Orphan Drug Designation

        03/23/2020

        Gilead Sciences Statement on Ensuring Continued  Supply of HIV Medicine Amid Coronavirus Outbreak

        03/22/2020

        Gilead Sciences Statement on Access to Remdesivir Outside of Clinical Trials

        02/05/2020

        Gilead Statement on U.S. Patent and Trademark Office Decision to Deny Request for Inter Partes Review of HIV PrEP Patents

        01/31/2020

        Gilead Sciences Statement on the Company’s Ongoing Response to the 2019 Novel Coronavirus (2019-nCoV)

        12/03/2019

        Gilead Statement on Commitment to Advancing Descovy for PrEP? Study in Cisgender Women & Adolescent Females

        11/07/2019

        Gilead Statement on U.S. Government Complaint Regarding HIV PrEP and PEP Patents

        08/21/2019

        Petitions to US Patent and Trademark Office on HIV PrEP Patents

        06/11/2019

        Gilead Sciences Statement on U.S. Preventive Services Task Force 'A' Recommendation for PrEP as an HIV Prevention Strategy

        05/14/2019

        Gilead Sciences Statement On Inaccurate Reporting On Truvada®

        04/10/2019

        Gilead Sciences Statement on Commitment to Providing Price Information

        04/04/2019

        Gilead Sciences Commits to Reducing our Global Greenhouse Gas Emissions by 25 Percent by 2025

        04/03/2019

        Gilead Sciences Announces $500,000 Grant To Pan American Development Foundation To Provide Emergency Health Services For Venezuelan Migrants And Host Communities In Colombia

        09/27/2018

        Gilead Sciences Statement on Grants to Spouses of Caricom Leaders Action Network (SCLAN) to Expand Access to Youth HIV Prevention and Care in the Caribbean

        09/24/2018

        A perspective from our CEO: Gilead Subsidiary to Launch Authorized Generics to Treat HCV

        09/07/2018

        Gilead Sciences Announces Steep Discounts for Ambisome to Treat Cryptococcal Meningitis in Low- and Middle-Income Countries

        05/02/2018

        Gilead Publishes 2017 Year in Review

        11/09/2017

        Gilead Sciences Announces 100 Percent Score on 2018 Human Rights Campaign Corporate Equality Index

        09/01/2017

        Gilead Implements Emergency Disaster Response Procedures to Ensure Medicine Access

        05/01/2017

        Gilead Publishes Year in Review 2016

        12/06/2016

        Gilead Recognized as Top Corporate Philanthropist in Funders Concerned About AIDS Report

        12/01/2016

        Gilead HIV Medicines Now Reaching 10 Million People in Developing Countries

        11/11/2016

        Statement on DISCOVER Study of F/TAF for PrEP

        08/01/2016

        Gilead Publishes 2015 Corporate Social Responsibility Report

        08/14/2015

        Gilead Supports PrEP Education to Increase HIV Prevention and Awareness

        08/12/2015

        Gilead Publishes Its 2014 Corporate Contributions Report

        Some of the content on this page is not intended for users outside the US.

        www.黄色网站.com